Technology Tracks Agenda
-
Upload
bioasia2015 -
Category
Documents
-
view
226 -
download
2
description
Transcript of Technology Tracks Agenda
DRUG DISCOVERY CONFERENCE
18th
February, 2014
PARTNERS: Dr. Reddy's Institute of LifeSciences (ILS), CSIR-Central Drug Research Institute (CDRI)
Draft Agenda
Key Note:
9:30 A.M - 10:15 A.M
Transforming to a Patient-Based Drug Discovery Approach
Dr. AV RamaRao, Founder & Chairman, AVRA Labs, Hyderabad*
Chair: Professor Goverdhan Mehta, Univ of Hyderabad and Dr. Prabhat Arya, DRILS,
Hyderabad
Subject 1 :
10:15 A.M -11:15 A.M
Emerging Targets: Protein-
Protein Interactions (PPI) and
Signaling Pathways
Focus: Cancer, Neurological
Disorders & Metabolic Disorders
Chair: Dr. Prabhat Arya, DRILS Hyderabad and Dr. J.B Gupta, GVKBio Hyderabad
Speakers:
• Dr. Sudhir Krishna, NCBS, Bangalore
• Dr. Sorab Dalal, ACTREC, Mumbai
• Dr. Prasenjit Mitra, DRILS Hyderabad
11:15 A.M -11:30 A.M TEA BREAK
Subject 2 :
11:30 A.M -12:30 P.M
Functional Assays and High-
throughput Screens
Chair: Dr. Kiranam Chatti and Dr. Prasenjit Mitra, DRILS Hyderabad
Speakers:
• Dr. Monalisa Chatterji, Astra Zeneca, Bangalore
• Dr. Kiranam Chatti, DRILS Hyderabad
• Dr. Prasenjit Mitra, DRILS Hyderabad
Subject 3 :
12:30 P.M - 01:30 P.M
3D Cell Biology for Screening
Chair: Dr. Gael Stephant, Paris* or Dr. Mike Renard*
• 3D Microtissues and Cell based Assays
• Toxicology Screens
Speakers:
• Dr. Wolfgang Moritz*/ Dr. Jens Kelm Insphero, Switzerland*
• Dr. Keith Murphy, Organovo, US*
01:30 P.M -02: 45 P.M LUNCH BREAK
02:45 P.M -03:15 P.M Innovation Talks: A Novel Versatile Human Cell Based in Vitro High Throughput
Genotoxicity Screen
Dr. Sunilkumar Sukumaran, Anthem Bioscience Bangalore
Subject 4 :
03:15 P.M -04:15 P.M
Chemical vs Biological Space
Chair: Dr. Prabhat Arya and Dr. Amit Mandal, DRILS Hyderabad
Speakers:
• Dr. G. Narahari Shastry, IICT Hyderabad
• Dr. Prabhat Arya, DRILS Hyderabad
Round Table :
4:15 P.M - 05-00 P.M
Problem Solving Agenda
(Round Table)
Strength of small molecules pipeline – Drivers & Barriers
Moderator - Dr. Prabhat Arya, DRILS Hyderabad and Mr. Arvindh Shanmugam,
Independent Consultant, Chennai
• Enzyme vs protein-protein interaction-based targets
• Functional assays
• Chemical vs biological space
• Upcoming challenges and opportunities for the CROs
• Basic science discovery to translational path
• Fostering academia-industry relationship to develop new research models
Panel:
Dr. JB Gupta - GVKBIO, Dr. Nishi - CEO Daiichi, Dr. CSN Murthy, Aurigene,Dr. Reddy's,
Jubilant, Dr. Raman Bakshi -Syngene, Dr. Satish Jindal - BMS, ChemBioTech, Dr. Renu
Swarup, DBT - BIRAC
BIO-THERAPEUTICS CONFERENCE
18th
February, 2014
Organizers:
Federation of Asian Biotech Association, Government of Andhra Pradesh, Pharmexcil, Ministry of
Commerce & Industry, Government of India
Partners:
Insight Bioventures India Private Limited, ACTREC, United States Pharmacopeia
Draft Program Agenda
9:30 - 10:15 Hrs
Keynote
Bio-Therapeutics - Unfolding Next Generation Biologics
Prevention of infections linked to human cancers
Prof. Dr. Harald zur Hausen (Nobel Laureate), University of Heidelberg, Germany
10:15 -11:15 Hrs
(Subject 1)
Next Generation
Biologics
mRNA CAR Engineered T-cell Immunotherapies
Dr. Madhusudan Peshwa, MaxCyte, Inc. Washington
Therapeutic Proteins for Diabetic foot ulcer (DFU)
Dr. Theresa O'Keefe, Mend Therapeutics Inc., Boston
Multispecifics: DVD-iG Technology
Dr. Subramanya Hegde *, AbbVie Inc., Boston
11:15 -11:30 Hrs Tea / Coffee Break
11:30 A.M -12:30 P.M
(Subject 2)
Cancer Bio-
Therapeutics
Chair: Dr. Shubhada Chiplunkar* , Director, ACTREC
Development & Commercialization of Enhanced Potency Dendritic Cell Vaccines for Cancer
Dr. Madhusudan Peshwa, MaxCyte, Inc. Washington
Lethal Seeds in the Womb: Endometrial Cancer Stem Cells Express Metastasis Tumor Antigen
Dr. Asha Nair, Rajiv Gandhi Centre for Biotechnology, Kerala
12:30-13:45 Hrs Lunch Break
13:45-15:30 Hrs
(Session 3)
Coordinated by United
States Pharmacopeia
Critical Quality Attributes of Biotherapeutic Proteins and Biosimilars
Dr. Sridevi Khambhampaty, Sr. Director, Dr. Reddy’s lab
Critical Quality Attributes of Vaccines
Dr. Mahesh Bhalgat, COO, Shantha Biotech
Quality Attributes of Biologic Medicines and USP Standards
Dr. Ranjan Chakrabarti, Vice President, United States Pharmacopeia-India
15:30-16:15 Hrs
(Session 4)
Bio-Engineering & Bio-
processing Innovation
Dr. Ralf Klein
ViruSure GmbH
Alternative expression system that will reduce the cost of production of therapeutic proteins
Dr. Jagmohan Singh, IMTECH
Rapid scalable. cGMP-compliant 'plug and play' platform for Manufacture of Multigram
Quantities of Recombinant Proteins, Antibodies & Vaccines
Dr. Madhusudan Peshwa, MaxCyte, Inc. Washington
16:15- 17.00Hrs Problem Solving Framework - Next Generation Biologics in India – Drivers & Resistors
* indicates invited confirmation awaited
BIO-ENERGY CONFERENCE 18
th February, 2014
PARTNERS: Ministry of New and Renewable Energy (MNRE), The Energy and Resources
Institute (TERI), & CSIR-Indian Institute of Chemical Technology (CSIR-IICT)
Draft Agenda
09:00-09:30 A.M INAUGURATION by Dr Satish Balram Agnihotri, Secretary to Government of India,
Ministry of New and Renewable Energy*
9:30 - 10:15 A.M
Keynote
Sustainability Assessment to Promote Holistic Bio-Energy Production – Feedstock,
Technology & Regulations
Dr. Jean-Marc Jossart *, Secretary General, AEBIOM-European Biomass Association,
Belgium (or)
Dr. David Hurlbut *, National Renewable Energy Laboratory, USA
10:15 - 11:15 A.M
(Session 1)
Bio-Feedstock
Supplies–
comparative analysis
of various feedstock
sources
Chair:
Mr. Amit Kumar *, Director, Energy-Environment Technology Development Division,
TERI, New Delhi
- Energy Plants – Alternatives
-Agri-residue biomass collection, logistics
-Algae
-Biomass
-Next Generation Alternatives
Proposed Speakers
• Dr. Murali Sastry, Director, DSM India Innovation Centre
• Dr Pankaj Patel - Director, Abellon CleanEnergy Ltd
• Dr.Ashwani Kumar, BioEnergia
• Dr. Shibu Jose, UM, Columbia, MO, USA
• Dr. D K Tuli , Executive Director & Centre Coordinator, DBT-IOC Advanced Bio-
Energy Research Centre, Indian Oil Corporation Ltd, Faridabad
• Dr Ahmed Kamal, IICT, Hyderabad
• Dr P Srinivasa Rao, Senior Scientist, ICRISAT, Patancheru, India
• Dr. Priyangashu Sarma , Fellow, TERI, New Delhi
11:15 -11:30 A.M Tea / Coffee Break
11:30-12:30 P.M
(Session 2)
BEMA:
Biotechnology,
Engineering, Micro-
Biology &
Agriculture
Chair – Mr. A P Dhussa *, Scientist-G/Advisor, Ministry for New and Renewable
Energy, Government of India, New Delhi /Dr Ahmed Kamal *, Outstanding Scientist,
CSIR-IICT, Hyderabad and Director, NIPER, Hyderabad
-Bio-Refinery Technologies
-Genetic Improvement of Energy Crops
-Strains and Enzyme Technology (Biomass Digestion)
-Mass Production of Energy Crops
Proposed Speakers
• Prof. K T Shanmugam, University of Florida, USA
• Prof. Hornung, Director - European Bioenergy Research Institute
• Dr. Arvind Lali, Centre Coordinator, DBT-ICT Center for Energy Biosciences,
Institute of Chemical Technology, Mumbai
• Mr. Laxmi Narasimhan, General Manager, Centre for Novel Catalytic
Materials, Shell Technology Centre, Shell India Marketing, Bangalore
• Dr S V Ramakrishna (earlier worked with Reliance and Praj in their biofuel
programs as research director)
• Mr. Subramani Ramachandrappa - CMD Richcore India
• DrAlok Adholeya, Director, Biotechnology and Management of Bio-resources
Division, TERI, New Delhi
• Dr. Ashok Pandey, Head, Centre for Biofuels, NIIST, Thiruvananthapuram
• (If a speaker needed on liquid fuels) Dr. Piyali Das, Fellow, TERI, New Delhi
12:30-1:30 P.M
(Session 3)
Industrial Bio-energy
& Commercial
Deployment
Chair - Mr. Pramod Chaudhari *, Executive Chairman, Praj Industries Limited and
Chairman, Praj Group, Pune, India
-Torreication Technology
-CHP Deployment & scalability
-DFC for Anaerobic Digestion
-Industrial bio-energy economics
Proposed Speakers
• Dr. Ludo Diels, Senior Scientist and Head of the Environmental and Process
Technology Centre, VITO, Belgium
• Dr Syed Isa Syed Alwi, CEO, AlgaeTech International, Malaysia
• Dr. R R Sonde, Executive Vice President, Research, Technology & Innovation,
Thermax India
• Mr. Sunil Dhingra, Senior Fellow, TERI, New Delhi
• Dr. Balu Sarma
1:30 - 2:45 P.M Lunch Break
2:45 - 3:15 P.M
Innovation Talk
K.Sudhakar, NIT-Bhopal & Five more speakers
3:15 - 4:15 P.M
(Session 4)
Regulations – New &
Renewable Energy
as a legislation &
Directive
Chair - Shri Alok Srivastava *, Joint Secretary, Ministry for New and Renewable
Energy, Government of India, New Delhi
Proposed Speakers
• Dr. Chris Mottershead, The Carbon Trust, London, UK / Richard Adams, NREL /
David Hurlburt NREL Policy Analysis group
• Dr. Renu Swarup, Adviser, Department of Biotechnology, Ministry of Science
& Technology, Government of India and Managing Director, Biotechnology
Industry Research Assistance Council
• Mr. Anil Kumar Jain, Adviser (Energy), Planning Commission, Government of
India
• Dr K V Raghavan, Vice President, FABA, Ex Director CSIR-IICT, Hyderabad
• Mr. K Krishan, Chairman CII Task force on Bioenergy and Chairman, MPPL
Renewable Energy Pvt. Ltd.
• Prof. Janaki/Dr Pankaj USA
4:15 - 5:30 P.M Problem Solving Agenda
Creating the Bio-Energy Economy of India – Drivers & resistors
Coordinated by PHARMEXCIL
For registrations Contact – [email protected] | Telephone: +91-40-6644-6477/6577
GENOMIC-PERSONALIZED MEDICINE CONFERENCE Hyderabad International Convention Center, Hyderabad
Chairman: Prof. Donald W. Weaver, Surgeon-in-Chief, Detroit Medical Center (DMC), Chief of
Surgery at Harper University Hospital, Chairman of Department of Surgery, Wayne State University
School of Medicine, USA
Conveners:
Dr. Ramesh B. Batchu, Associate Professor, Dept Surgery, School of Medicine Director,
Division of Surgical Oncology & Developmental Therapeutics, Dept Immunology and
Microbiology, John D Dingell VAMC, Wayne State University
Dr Cirino Botta, MD, Medical Oncology Unit, Fondazione Tommaso Campanella & Magna
Graecia University of Catanzaro, Italy
Draft Program Agenda
09:30-10:00 Hrs “Personalized Medicine: Tailor-made for individual patient”
Personalized medicine is the ability to determine an individual's unique molecular
characteristics to propose customization of medical care more finely suited to a patient.
The availability of genetic information due to successful human genome project has
played a major role in the ability to predict an individual's susceptibility to diseases.
This will allow protocols designed specifically based on the patient’s response to
treatment.
Prof. Donald W. Weaver MD, FACS, Surgeon-in-Chief, Detroit Medical Center (DMC), Chief
of Surgery at Harper University Hospital, Chairman of Department of Surgery, Wayne State
University School of Medicine, USA
10:00-10:20 Hrs Adeno-associated Viral vectors in Genomic Medicine and cell based treatment
Gene therapy with traditional viral vectors is limited by a variety of practical and
theoretical concerns, such as the immunogenicity of viral capsid proteins and insertional
mutagenesis. Adeno-associated virus (AAV) is a small, 4.7kb, non-enveloped DNA virus
initially identified as a contaminant in adenoviral preparations. Bioengineered
recombinant AAV (rAAV) vectors are preferred for gene therapy due to their lack of
pathogenicity, wide range of infectivity, and ability to establish long-term transgene
expression in non-dividing cells. Furthermore, with only a modest frequency of
integration into the host genome, they avoid insertional mutagenesis. Finally, rAAV
vectors per se induce only weak innate immune responses when compared to other
Coordinated by PHARMEXCIL
For registrations Contact – [email protected] | Telephone: +91-40-6644-6477/6577
viral-based vectors. rAAV vectors have yielded promising results in an increasing
number of somatic gene therapy clinical trials without any significant adverse events.
However, despite the well-established safety of rAAV vectors for in vivo gene transfer,
several challenges remain, such as achieving high levels of transduction in targeted
organs and inhibiting cytoplasmic degradation of a high percentage of virions during
intracellular trafficking to the nucleus. Indeed, rAAV capsids are phosphorylated,
marking them for ubiquitination followed by proteasome-mediated degradation in the
cytosol. Thus, higher doses of vectors are needed to obtain therapeutically relevant
concentrations in patients. The development of next generation of capsid-modified rAAV
vectors, which bypass ubiquitination and proteasome degradation, leading to high
efficiency gene transfer and transgene expression at reduced doses, and their utility in
genomic medicine will be discussed.
Dr. Arun Srivastava, George H. Kitzman Professor of Genetics and Chief of Division of Cellular
& Molecular Therapy in the Departments of Pediatrics, and Molecular Genetics & Microbiology,
and Powell Gene Therapy Center, University of Florida, USA
10:20-10:40 Hrs Urological cancers, biomarkers and cancer pathway inhibitors
Immune status of every tumor and the way its cells respond to the local environment is
different, based on the genetic profile of patients. The tumor grade may be the same from
patient to patient, but the pathways for escape and resistance may be different.
Genomics and proteomics-guided treatment of individual patients is the direction we
should be taking to manage malignancies. This holds true not only when it comes to
predicting progression and aggression of tumors where we need to be pairing
therapeutics based on the genetic/protein marker. Each patient with urological cancer
has a distinct histology, a different clinical course and responds differently to therapy.
For example genomic studies in identifying the genes for kidney cancer, such as
fumarate hydratase, and succinate dehydrogenase have significantly altered the ways in
which patients with kidney cancer are managed.
Dr. Jose Pontes, MD, Urologist, Detroit, MI, USA
10:40-11:00 Hrs Tea / Coffee Break
11:00-11:20 Hrs Gene-based treatment for Head and Neck Cancers
Although some head and neck cancers are diagnosed early in the disease progression,
silent lesions unfortunately are not diagnosed until regional spread has already
occurred. The stage at the time of diagnosis for cancer of larynx with early symptoms of
hoarseness is much lower than that of a base of tongue cancer, which often lacks
symptoms, until later in the disease course. Infection with human papilloma virus
(HPV) increases one’s odds of developing squamous cell carcinoma of the oral pharynx.
As smoking has decreased, the incidence of HPV associated cancers has increased.
Understanding the genetic basis of this specific subtype of cancer could allow
therapeutic targeting of affected pathways for a stratified medicine approach. Gene
profile analysis of various head and neck cancers revealed altered pathways in p53 and
Coordinated by PHARMEXCIL
For registrations Contact – [email protected] | Telephone: +91-40-6644-6477/6577
Rb mutation and copy number alteration of PI3 kinase pathway. Additional observations
of alternative pathways have been made in cancers of the thyroid. Whole genome
sequencing and identification of gene expression patterns will be required to gain a
complete understanding of the genetic basis of head and neck cancers to provide the
foundation for the development of effective forms of therapy.
Prof. John R Jacobs MD FACS, Departments Otolaryngology Head and Neck Surgery, Wayne
State University, Karmanos Cancer Center, USA
11:20-11:40 Hrs Genetic Immunotherapy with Dendritic Cells for Individualized Cancer Vaccine
Dendritic cells (DC) are highly specialized antigen-presenting immune cells and key
regulators of the immune responses that orchestrate innate and adoptive immunities
throughout the body. They are responsible for identifying tumor markers to activate
cytotoxic T lymphocytes, which then multiply and attack only the diseased cells, but not
normal healthy cells. This is a potent form of immunotherapy to harness the body's own
immune system to fight cancer. Use of non-pathogenic recombinant adeno-associated
viral (rAAV) vectors can achieve high levels of intracellular tumor specific gene
expression in DCs with much lower doses of vector and generation of robust cellular
anti-tumor immune responses. Gene-vector based immunotherapy with DCs would
pave the way for development of a therapeutic vaccine strategy to achieve durable tumor
regression specific to individual patients.
Prof. Selvarangan Ponnazhagan, Endowed Professor in Experimental Cancer Therapeutics,
The University of Alabama at Birmingham, USA
11:40-12:00 Hrs Personalized Therapeutic Vaccines
Therapeutic vaccinology will allow the development of personalized vaccines based on
our increasing understanding of immune response phenotype: genotype information.
Rapid advances in developing such data are already occurring for numerous diseases
and newly available data suggest that some vaccine-related adverse events may also be
preventable based on genetic prediction.
Dr. Bala Krishna Kolli, Rosalinda Franklin University of Medicine and Science, North
Chicago, IL, USA
12:00-12:20 Hrs Role of Bioinformatics in Personalized Medicine
In the genomic era: doctors and patients will have access to genetic data to customize
medical treatment. In recent past, molecular science has made many advances to benefit
medicine, including the Human Genome project, International HapMap project and
genome wide association studies (GWASs) (International HapMap Consortium, 2005).
Single nucleotide polymorphisms (SNPs) are now recognized as the main cause of
human genetic variability and are already a valuable resource for mapping complex
genetic traits. Thousands of DNA variants have been identified that are associated with
diseases and traits. By combining these genetic associations with phenotypes and drug
response, personalized medicine will tailor treatments to the patients’ specific genotype.
Coordinated by PHARMEXCIL
For registrations Contact – [email protected] | Telephone: +91-40-6644-6477/6577
Anticancer drugs which target to specific cancers, and use of pharmacogenetic dosing
algorithm, reduction of incidence of adverse events by screening for susceptible
genotypes for certain drugs underscore the importance of bioinformatics approach in
personalized medicine.
Dr. Ravindra B Potti, Associate Professor, Department of Biotechnology, Sreenidhi Institute of
Science and Technology, Hyderabad
12:20-13:00 Hrs Interaction and Close
Bio-IT Conference 19
th February, 2014
Draft Agenda
Key Note:
9:30 A.M - 10:15 A.M
BioPharma Big Data Paradigm
Dr. Nitish Chawla, University of Notre Dame, Indiana, US
(2013 IBM Big Data Innovation Award winner)
Subject 1 :
10:15 A.M - 11:15 A.M
Computational
Therapeutics
Session Chair: Dr. Vellarkad N. Viswanadhan, Jubilant Biosys
Computational Drug Design
Dr. Frank Hollinger - Sphaera Pharma
Computation Guided Vaccine Design Integrative approach for designing of Epitope-based
vaccine using in silico platform OSDD Linux
Dr. GPS. Raghava – IMTECH
Blast Off! Exploring the universe of biochemical reactions
Dr. Rahman Syed Asad., EMBL – EBI, Cambridge, UK
11:15 A.M - 11:30 A.M TEA BREAK
Subject 2 :
11:30 A.M - 12:30 P.M
Cross Platform Omics for
Translation Research
BioMarker Discovery for Translational Prediction
Dr. Pramila Tata - Strand Life Sciences
Integrative Omics – Interactome Models
Mr. Jignesh Bhate – Molecular Connections
Translational Informatics
Dr. Ajay Shah, City of Hope, CA, US*
Systems Pharmacology
Dr. Rajgopal Srinivasan – TCS Innovation Labs
Subject 3 :
12:30 P.M - 1:30 P.M
Data capture & Analytics
Chair: Mr. Raghu Rangaswamy, Schroedinger
Preserve, Protect & Collaborate via Scilligence Informatics (ELN)
Mr. Rajiv Hotchandani- Scilligence
Data Pipeline Management: Pipeline Pilot
Proposed: Accelrys
Registration Systems (Chemical & Biological)
Mr. Ivan Solt – Chemaxon, Hungary*
Process Analytics: Reaction Data Kit Demonstration
Mr. Ramakrishna Bodi, KNIME*
1: 30 P.M - 02:30 P.M Lunch Break
02:30 P.M - 03:00 P.M
Innovation Talks
Subject 4 :
03:00 P.M - 04:00 P.M
Big Omics Data
Management, Challenges
Drug R & D Knowledge Mining Made Simple: A Scilligence Perspective
Dr. Jinbo Lee, CSO, Scilligence
Cloud Computing and Innovations for Optimizing Life Sciences Research
Ms. Krittika Sasmal , iOMICS, InterpretOmics
SaaS, IaaS and PaaS options for IT Investment Optimization
Proposed Speaker from Accenture, IBM
Round Table :
4:00 P.M - 04-30 P.M
Problem Solving Agenda
Problem Solving Agenda:
Bio-IT – Leveraging IT Investments in Bio-Pharma R&D (Drivers & Barriers)
REGENERATIVE MEDICINE CONFERENCE
19th
February, 2014
PARTNERS: Integrative Regenerative Medicine (IGEN) Center, Society for Tissue Engineering &
Regenerative Medicine (STERMI), Sankara Netralaya Translational Research Institute (SNTRI)
Draft Agenda
Key Note:
9:30 A.M - 10:15 A.M
Chair: Prof. Zee Upton, Queensland University of Technology
Guest: Dr. Michael West, Chairman BioTime Inc.
Doing more with less: Frugal innovation in Regenerative Medicine –
Dr. Mahendra Rao, Director The NIH Center for Regenerative Medicine, USA
Subject 1 :
10:15 A.M -11:15 A.M
Comparative
Therapeutic Potential
of various Stem Cell
Chair: Dr. Utpal Banerjee, UCLA*
Embryonic Source (Pure Stem)
Dr. Jeffey Janus, ESI Bio/BioTime (or) Dr. James Kehler, BioTime
Induced Pluripotent Stem Cells –
Dr. Ullas Mony*
Dr. Alok Srivastava, CMC*
Dr. James Byrne, UCLA*
Adult stem cells, their potential and their comparison with ESCs
Dr. Chandra Viswanath - Reliance Life Sciences
Therapeutic potential of Hematopoietic and Mesenchymal stem cells derived from cord tissues
Dr. Lalitha Limaye, NCCS, Pune
11: 15 A.M–11: 30 P.M TEA BREAK
Subject 2 :
11:30 A.M -12:30 P.M
Characterization,
Reprogramming,
Differentiation &
Analysis of Stem Cells
Chair: Dr. Vincent Zurawski, Hepregen Corporation*
Biomarker discovery for stem cells using omics,
Dr. Vivek Tanavde, Bioinformatics Institute, Singapore
Cell Reprogramming
Dr. P Chandrashekar, inStem*
Epigenetic analysis & Characterization
Dr. Rachna Goyal, Lonza
Engineering Adult Stem Cells to Enhance their Potency & Therapeutic Efficacy
Dr. Madhusudan Peshwa, MaxCyte, Inc. Washington
Subject 3 :
12:30 P.M -01:30 P.M
3D Biology & Tissue
Engineering
Chair: Dr. Seeram Ramakrishna - NUS, Center for Nanofibres & Nanotechnology
Biomimetic Building Blocks
Dr. Jaywant Phophase, IGEN, Linkoping University, Sweden
3D Biology for RM
Dr. Gael Stephant, Paris*
Tissue Engineering & Bio-printing Technology
Dr. Sourabh Ghosh, IIT Delhi
Bio-printing Technology
Dr. Keith Murphy, Organovo, San Diego*
Dr. Michael Renard, Organovo, San Diego*
Brain Organoids
Dr. Juergen Knoblich, IMBA - Institute of Molecular Biotechnology, Austria*
(Or)
Liver Organoids
Dr. Nuria Montserrat, Centre of Regenerative Medicine in Barcelona*
1:30 P.M -2:30 P.M LUNCH BREAK
02:30 P.M -03:00 P.M Innovation Talks
Subject 4 :
3:00 P.M -04:00 P.M
Specialty Trends
Chair: Prof. Nisha R Agrawal, Banaras Hindu University, Varanasi
Bone & Cartilage
Dr. Sudhir Kumar Reddy, ISCO Cell Therapeutics
Neural
Dr. NK Venkatarama*/Dr. Basha Paspala
Cardiac
Dr. Arjun Deb, MD, Board of Stem Cells, UCLA, USA*
Ophthalmology
Dr. Krishna Kumar, Vision Research Foundation, Sankara Nethralaya
Dr. Doris Taylor, Centre for Cardiovascular, University of Minnesota*
Round Table :
4:00 P.M – 04:30 P.M
Problem Solving Agenda : Stem Cell & Regenerative medicine - Drivers & Barriers
Medical Electronics and Devices Conference 19th February, 2014
DRAFT AGENDA
09:30 – 10:15 Hrs INAUGURAL CEREMONY
Chief Guest:
Minister of State, Department of Commerce, Government of India*
Guests of Honour:
• Shri J. Satyanarayana, IAS, Secretary to the Government of India, Department of Electronics and Information Technology (DEITY), Ministry of Communications & Information Technology (Government of India)*
• Shri. Pradeep Chandra IAS, Principal Secretary to the Government of Andhra Pradesh, Department of Industries and Commerce
Keynote Address: India’s vision and Strategy on MedTech Dr. Ajay Kumar IAS, Joint Secretary to the Government of India, Dept. of Electronics and Information Technology*
10:15 – 11:15 Hrs Medical Technologies – India for India
“The Indian Medical Device & Equipment market is currently valued at $ 4.4 billion and is expected to grow to around $ 5.8 billion by 2014 and $ 7.8 billion by 2016, growing at a CAGR of 15.5 per cent", according to an industry report. As the sector gains traction continually over the years, there is a perpetual demand for high quality products. There were around 356 registered manufacturing units producing medical devices of the value of outputs of `312 crores in 2009‐10. There are only few units manufacturing medical devices compared to the growing manufacturing sector in India. The session will focus on the gap between the supply and demand such that the Indian production can cater to the local demand than relying on exports
Lead Speaker:
Mr. M.R. Srinivas Prasad, CEO , Philips Innovation Campus
Panelists:
• Mr. M.R. Srinivas Prasad, CEO , Philips Innovation Campus
• Mr. Suresh Sharma, Chairman & Managing Director, Allengers Medical Systems Limited*
• Mr. Ajit G Nambiar, Chairman & Managing Director, BPL Healthcare*
• Dr. K. K. Kalra, CEO, National Accreditation Board for Hospitals & Healthcare Providers (NABH)
• Shri. Arun Sachdeva, Senior Director (Scientist‐G), Department of Electronics and Information Technology (DEITY), Government of India
Moderator: Mr. Mahadevan Narayanamoni, Partner, Corporate Finance and Life Sciences, Grant Thornton
11:15 – 11:30 Hrs TEA / COFFEE BREAK
11:30 – 11:45 Hrs Opportunities in Gangwon (South Korea)
11:45 – 12:30 Hrs MedTech – Ensuring Quality and Patient Safety
Growing demand of efficacious and quality treatments has accelerated the growth of MedTech Sector. As with every new emerging technology, there are potential risks with such new technologies, and testing & calibration holds the key. Availability of skilled manpower and huge talent pool of engineers in India makes it a strategic destination for testing and calibration forglobal companies. The session shall focus on ways and means to enhance patient safety and quality of medical technologies through strengthening the testing and calibration laboratories in
India and the potential role that Industry and Government (both state and central) have to play
Chairman: Mr. S. Kishore Kumar, Scientist‐F & Head, Medical and Hospital Planning, Bureau of Indian Standards, Government of India
Panelists:
• Mr. Sundeep Rao, Vice President, Philips Electronics India Limited*
• Mr. Suresh Sugavanam. Vice President & Managing Director at Underwriters Laboratories
• Mr. G. Kalyan Varma, Country Head, Products Business Stream, TUV Rheinland India
• Dr. G.S.K. Velu, Managing Director, Trivitron Laboratories*
• Dr. Chander Shekhar, Scientist ‐ 'F', Indian Council of Medical Research (ICMR)
• Dr. Devasis Guha, Head, R & D, HLL Lifecare Limited*
Moderator: Dr. Girdhar J Gyani, Director General, Association of Healthcare Providers (India)*
12:30 – 13:30 Hrs India as Manufacturing Hub
The influx of Medical Electronics technology has reinforced the existing Healthcare infrastructure in various ways right from digitizing medical test, diagnostic and therapeutic procedures to enhancing the reach of Healthcare through telemedicine and Health IT. A number of international companies have set up manufacturing facilities in India and given the tremendous benefits of cost economics, India promises to be the manufacturing hub for MedTech
Lead Speaker:
Mr. Vikram Damodaran, Chief Technical Officer, GE Healthcare India*
Panelists:
• Mr. Kaustubh Patil, Program Manager, Medtronic India Development Center*
• Mr. Subramanian, Director, SCS systems*
• Mr. Vinayak Khandeparker, Quality Head, Siemens India*
• Dr. Shahid Jameel, Senior Scientist and Group Leader, ICGEB*
Moderator: Mr. Vijay Simha, CEO, One Breadth Inc.
13:30 – 14:30 Hrs LUNCH BREAK
14:30-15:30 Hrs Creating a conducive Policy Environment in India: Way Forward
While the sector faces challenges in particularly in terms of low penetration, high capital requirement, complex rules & guidelines, acceptability, awareness, etc., the future looks extremely promising with the increased public spending & private investment in healthcare, health insurance schemes, public private partnership (ppp) route to innovation, etc. This panel is structured to be a discussion with the key policy makers to understand from them on enabling a fostering environment for the growth of the sector
Panelists:
• Dr. Ajay Kumar IAS, Joint Secretary to Government of India, Department of Electronics and Information Technology (DEITY)*
• Mr. S. Kishore Kumar, Scientist‐F & Head, Medical and Hospital Planning, Bureau of Indian Standards, Government of India
• Shri S. B. S. Reddy, ITS, Regional Jt. DGFT (Directorate General of Foreign Trade)
• Mrs. Anuradha Gupta, Joint Secretary, Ministry of Health & Family Welfare (PNDT)*
• Dr. Sadhana Srivastava, Scientist E, IPR Unit, Department of Health Research, Indian Council of Medical Research (ICMR)
• Dr. Rashid Hasan, Director, Ministry of Environment & Forests (MoEF)*
Moderator: Mr. Karan Singh, Partner, Bain & Company*
15:30-15:45 Hrs China Medical City-Opportunities in China
15:45 -16:30 Hrs Concluding Remarks by the coordinators and Event Close
Mr. Sudhakar Mairpadi, Head Regulatory Affairs, Philips Mr. Vibhav Garg, Head, Health Economics & Government Affairs, Boston Scientific